Press releases

ORYZON receives European Medicines Agency approval to initiate a Phase Ib study of iadademstat in sickle cell disease

ORYZON reports financial results and corporate update for half-year ending June 30, 2025

Expanding analyst interest in ORYZON

ORYZON continues to strengthen its patent portfolio for vafidemstat

ORYZON to host virtual KOL event on July 9, 2025

ORYZON announces submission of Phase III protocol to FDA to initiate PORTICO-2 trial of vafidemstat in Borderline Personality Disorder (BPD) patients

ORYZON to attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29

ORYZON to provide corporate progress updates at several events in May-June

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)